Canopy Rivers’ (TSXV: RIV.V) (OTC: CNPOF) portfolio company TerrAscend Corp. (CNSX: TER) (OTC: TRSSF) based in Mississauga, Canada recently announced that it has received an amendment to its license from Health Canada to enable the company to sell cannabis oils from its EU-GMP certified facility in Mississauga, Ontario. TerrAscend also announced that it will begin the sale of its cannabis oil immediately through Solace Health (www.solacehealth.com). The sale will extend into the Canadian adult-use market in the coming weeks.
Speaking on the License amendment, TerrAscend CEO, Michael Nashat, said, “The addition of oils to our product line enables us to better meet the needs of our patients and customers, who demand safe, standardized products. It also helps us meet the growing demand for non-combustible cannabis products. As with every product, we make our oils with a relentless, pharmaceutical-grade focus on quality, safety, and consistency. Today is an important milestone in our journey to be the world’s most trusted provider of top quality cannabinoid products.”
TerrAscend is also making frantic efforts to be able to export its oils to international medical markets. Just two months earlier, TerrAscend announced that it has received a Good Manufacturing Practice (GMP) certificate in accordance with the rules governing medical products in the European Union.
In a congratulatory message to TerrAscend, the President and CEO of Canopy Rivers, Narbe Alexandrian said, “With another key milestone achieved by TerrAscend in a matter of a few short months, the company continues to demonstrate its ambition to become a global provider of pharmaceutical-grade cannabis products. Cannabis oil is gaining popularity in Canada, the US and in other emerging global medical markets, and this sales license enables TerrAscent to meet growing demand for non-combustible cannabis products.”
Curious about how you can make money investing in cannabis? Sign up the Cannin Premium Membership, including ai automated trading, access to all analysis and reports for only $99 / month, a fraction of what you can earn using these tools. Or sign up for free Cannabis investing news direct to your inbox. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.